# An Open-Label Study of Once-Daily Oral Administration of Esomeprazole 40 mg in Patients With Symptoms of Gastroesophageal Reflux Disease (GERD)

> **NCT00242736** · PHASE4 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 350 (—)

## Conditions studied

- GERD

## Interventions

- **DRUG:** Esomeprazole

## Key facts

- **NCT ID:** NCT00242736
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** —
- **Final completion:** 2006-01
- **Target enrollment:** 350 (—)
- **Last updated:** 2009-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00242736

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00242736, "An Open-Label Study of Once-Daily Oral Administration of Esomeprazole 40 mg in Patients With Symptoms of Gastroesophageal Reflux Disease (GERD)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00242736. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*